GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amarantus Bioscience Holdings Inc (OTCPK:AMBS) » Definitions » EPS (Diluted)

Amarantus Bioscience Holdings (Amarantus Bioscience Holdings) EPS (Diluted) : $-4.17 (TTM As of Dec. 2015)


View and export this data going back to 2008. Start your Free Trial

What is Amarantus Bioscience Holdings EPS (Diluted)?

Amarantus Bioscience Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2015 was $-4.17. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2015 was $-4.17.

Amarantus Bioscience Holdings's EPS (Basic) for the six months ended in Dec. 2015 was $-4.17. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2015 was $-4.17.

Amarantus Bioscience Holdings's EPS without NRI for the six months ended in Dec. 2015 was $-4.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2015 was $-4.38.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Amarantus Bioscience Holdings EPS (Diluted) Historical Data

The historical data trend for Amarantus Bioscience Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarantus Bioscience Holdings EPS (Diluted) Chart

Amarantus Bioscience Holdings Annual Data
Trend Oct08 Oct09 Oct10 Dec11 Dec12 Dec13 Dec14 Dec15
EPS (Diluted)
Get a 7-Day Free Trial -12.00 -6.00 -4.50 -5.71 -4.17

Amarantus Bioscience Holdings Semi-Annual Data
Oct08 Oct09 Oct10 Dec11 Dec12 Dec13 Dec14 Dec15
EPS (Diluted) Get a 7-Day Free Trial -12.00 -6.00 -4.50 -5.71 -4.17

Competitive Comparison of Amarantus Bioscience Holdings's EPS (Diluted)

For the Biotechnology subindustry, Amarantus Bioscience Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarantus Bioscience Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amarantus Bioscience Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Amarantus Bioscience Holdings's PE Ratio falls into.



Amarantus Bioscience Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Amarantus Bioscience Holdings's Diluted EPS for the fiscal year that ended in Dec. 2015 is calculated as

Diluted EPS (A: Dec. 2015 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-25.214-11.844)/8.878
=-4.17

Amarantus Bioscience Holdings's Diluted EPS for the quarter that ended in Dec. 2015 is calculated as

Diluted EPS (Q: Dec. 2015 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-25.214-11.844)/8.878
=-4.17

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2015 was $-4.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amarantus Bioscience Holdings  (OTCPK:AMBS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Amarantus Bioscience Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Amarantus Bioscience Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarantus Bioscience Holdings (Amarantus Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
45 Wall Street, Suite 920, New York, NY, USA, 10005
Amarantus Bioscience Holdings Inc is a biopharmaceutical company. It is focused on developing therapeutic products for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company's prime therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia. The group's diagnostics division is dedicated to the development and commercialization of neurology diagnostic products. Its diagnostic product, LymPro Test is a blood-based assay to diagnose Alzheimer's disease.
Executives
Flanigan Conn other: Former Director 1601 BLAKE STREET, SUITE 310, DENVER CO 80202
Robert Edward Farrell officer: CFO BIOVEST INTERNATIONAL, INC., 300 S HYDE PARK AVENUE, SUITE 210, TAMPA FL 33606
Joseph Rubinfeld director C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568